On December 22, 2025, Oncotelic Therapeutics, Inc. announced open access to its PDAOAI platform for biomedical data analysis.
Key Highlights:
PDAOAI platform extracts signals from complex datasets.No need for bespoke LLMs on proprietary data.Access to TGF-β literature via Discord channel.Over 125,000 PubMed abstracts available for research.
Original SEC Filing: Oncotelic Therapeutics, Inc. [ OTLC ] – 8-K – Dec. 23, 2025
Disclaimer
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.